Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced its participation in two upcoming investor conferences in September 2024:

• The Morgan Stanley 22nd Annual Global Healthcare Conference on September 4th at 4:55 p.m. ET in New York, NY
• The Cantor Fitzgerald Global Healthcare Conference 2024 on September 19th at 10:55 a.m. ET in New York, NY

Both events will feature fireside chats with Arcus Biosciences' management team. Live webcasts of these sessions will be available on the company's website under the 'Investors & Media' section, with replays accessible after the events.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September:

Morgan Stanley 22^nd Annual Global Healthcare Conference
Date: Wednesday, September 4^th, 2024 at 4:55 p.m. ET
Location: New York, NY
Format: Fireside Chat

Cantor Fitzgerald Global Healthcare Conference 2024
Date: Thursday, September 19^th, 2024 at 10:55 a.m. ET
Location: New York, NY
Format: Fireside Chat

Live webcasts of the fireside chats and panel will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240821933473/en/

Investor Inquiries

Pia Eaves (Banerjee)

Head of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

When is Arcus Biosciences (RCUS) participating in the Morgan Stanley Healthcare Conference?

Arcus Biosciences (RCUS) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, 2024 at 4:55 p.m. ET in New York, NY.

What is the format of Arcus Biosciences' (RCUS) presentation at the Cantor Fitzgerald Global Healthcare Conference 2024?

Arcus Biosciences (RCUS) will participate in a fireside chat format at the Cantor Fitzgerald Global Healthcare Conference 2024 on Thursday, September 19th, 2024 at 10:55 a.m. ET in New York, NY.

How can investors access the webcasts of Arcus Biosciences' (RCUS) investor conference presentations?

Investors can access live webcasts of Arcus Biosciences' (RCUS) presentations by visiting the 'Investors & Media' section of the company's website at www.arcusbio.com. Replays will be available following the live events.

What is the focus of Arcus Biosciences (RCUS) as a company?

Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer.